A rare case report of a primary large-cell neuroendocrine carcinoma of the breast with coexisting Paget disease

Psoma, Elisavet; Nikolaidou, Olga; Stavrogianni, Thomai; Mavromati, Areti; Lytras, Konstantinos; Xirou, Persefoni; Koumbanaki, Melanie; Panagiotopoulou, Dimitra

doi:10.1016/j.clinimag.2011.10.004

Cited by 9 publications

(7 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Sur le plan radiologique, les tumeurs neuroendocrines primitives du sein se présentent généralement, sur les clichés de mammographie, comme une opacité arrondie à contours flous, parfois bien limitée faisant évoquer une tumeur bénigne (fibroadénome ou kyste). Les opacités stellaires ou spiculées étaient rares [13]. Cependant, Gunhan-Bilgen et al ont décrit que les signes radiologiques communs des tumeurs neuroendocrines primitives du sein étaient une masse de haute densité avec des marges principalement spiculées ou lobulées sur la mammographie [14].…”

Section: éTude Clinique Et Diagnostic Positifunclassified

“…Cependant, Gunhan-Bilgen et al ont décrit que les signes radiologiques communs des tumeurs neuroendocrines primitives du sein étaient une masse de haute densité avec des marges principalement spiculées ou lobulées sur la mammographie [14]. Les microcalcifications sont moins fréquente dans les tumeurs neuroendocrines primitives du sein que dans les autres carcinomes mammaires [10,13].…”

Section: éTude Clinique Et Diagnostic Positifunclassified

“…La probabilité de survie globale à 5 ans était de 73 %. Toutes les patientes ont été opérées par mastectomie radicale modifiée dans 13 …”

unclassified

See 2 more Smart Citations

Tumeurs neuroendocrines primitives du sein : étude rétrospective de 21 cas et revue de la littérature

Feki

Fourati

Mnif

et al. 2015

Cancer/Radiothérapie

View full text Add to dashboard Cite

Section: éTude Clinique Et Diagnostic Positifunclassified

See 1 more Smart Citation

Tumeurs neuroendocrines primitives du sein : étude rétrospective de 21 cas et revue de la littérature

Feki

Fourati

Mnif

et al. 2015

Cancer/Radiothérapie

View full text Add to dashboard Cite

“…To our knowledge, there have been only six published case reports of large cell NECB with information on systemic treatment (Table ): two from Morocco and one from Spain, Japan, Korea, and Greece . While the number of cases is few, it appears that the age at diagnosis of large cell NECB tends to be far below the average age for IDC, NOS, as was the case for our patient who was diagnosed at age 34.…”

Section: Discussionmentioning

confidence: 55%

Primary Large Cell Neuroendocrine Carcinoma of the Breast, a Case Report with an Unusual Clinical Course

et al. 2015

View full text Add to dashboard Cite

Large cell neuroendocrine carcinoma of the breast (NECB) is an extremely rare type of breast cancer; little is known about effective chemotherapies, and data on pathologic response to treatment are unavailable. We report the case of a 34-years-old woman with large cell NECB with initial clinical and pathologic evidence of treatment response to anthracycline-containing neo-adjuvant therapy. Histologic reassessment early during anthracycline chemotherapy revealed cell death with necrosis of 50% of the tumor cells seen in the biopsy specimen. After completing neo-adjuvant chemotherapy, the patient underwent breast-conserving surgery. Pathologic evaluation of the surgical specimen showed a partial response but margins were positive for residual carcinoma. Despite repeated neo-adjuvant chemotherapy, radiotherapy, and surgical resection, the tumor grew rapidly between surgeries and recurred systemically. Therefore, we review the literature on large cell NECB and its treatment options.

show abstract

“…Also, we included large cell neuroendocrine carcinoma which was newly added into the neuroendocrine breast neoplasms in the 5th Edition of the World Health Organization (WHO). At present, only 7 cases of large cell neuroendocrine carcinoma of the breast have been reported [14][15][16][17][18][19][20] . Finally, 208 patients with breast NEC were identi ed in the present study.…”

Section: Discussionmentioning

confidence: 99%

Neuroendocrine Carcinoma of the Breast is More Aggressive Than Breast Invasive Ductal Carcinoma: A Propensity Score Matching Study Based on SEER Database

Chen¹,

Xue²,

Xu³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Neuroendocrine carcinoma (NEC) of the breast is a very rare malignant tumor whose clinic pathological features and prognosis are not well defined. The aim of this study was to compare the clinic pathological features and clinical outcome between breast neuroendocrine carcinoma and breast invasive ductal carcinoma (IDC) and to know the independent prognostic risk factors of NEC.Method Patients with breast NEC and breast IDC were identified through the Surveillance, Epidemiology, and End Results (SEER) database from 2010 to 2015. Then we compared the clinic pathological features and outcome between the two cohorts. Propensity score matching (PSM) was performed to balance the effects of baseline clinic pathological differences. Potential prognostic factors of breast NEC were identified by the univariate and multivariate Cox analysis.Results In total, we identified 208 patients with breast NEC and 275,878 cases with breast IDC.Compared with IDC, NEC was significantly correlated with higher stage, larger tumor size, more distant transfers and no population of HER2 enriched subtype. There were significant differences on the choice of treatment therapy between NEC and IDC (p=0.000). More patients chose not to undergo surgery (35.1% vs. 9.0%), and fewer patients chose breast conserving surgery than IDC patients (32.2% vs. 51.1%). Compared with IDC patients, NEC patients were more likely to choose chemotherapy (p=0.039) and more conservative in radiotherapy (p=0.000). The 66-month overall survival (OS) rate in NEC and IDC was 44.5% and 80.2% before PSM and was 49.8% and 71.4% after PSM, respectively. The 66-month breast cancer specific survival (BCSS) rate in NEC and IDC was 56.3% and 88.8% before PSM and was 54.1% and 80.5% after PSM, respectively. Finally, we identified independent prognostic factors, age, stage, pathological type, distant metastasis, chemotherapy, and molecular typing. Conclusions Breast NEC has distinct clinic pathological features and a significantly worse clinical outcome than common IDC.

show abstract

A rare case report of a primary large-cell neuroendocrine carcinoma of the breast with coexisting Paget disease

Cited by 9 publications

References 7 publications

Tumeurs neuroendocrines primitives du sein : étude rétrospective de 21 cas et revue de la littérature

Tumeurs neuroendocrines primitives du sein : étude rétrospective de 21 cas et revue de la littérature

Primary Large Cell Neuroendocrine Carcinoma of the Breast, a Case Report with an Unusual Clinical Course

Neuroendocrine Carcinoma of the Breast is More Aggressive Than Breast Invasive Ductal Carcinoma: A Propensity Score Matching Study Based on SEER Database

Contact Info

Product

Resources

About

A rare case report of a primary large-cell neuroendocrine carcinoma of the breast with coexisting Paget disease

Cited by 9 publications

References 7 publications

Tumeurs neuroendocrines primitives du sein : étude rétrospective de 21 cas et revue de la littérature

Tumeurs neuroendocrines primitives du sein : étude rétrospective de 21 cas et revue de la littérature

Primary Large Cell Neuroendocrine Carcinoma of the Breast, a Case Report with an Unusual Clinical Course

Neuroendocrine Carcinoma of the Breast is More Aggressive Than Breast Invasive Ductal Carcinoma: A Propensity Score Matching Study Based on SEER&nbsp;Database

Contact Info

Product

Resources

About

Neuroendocrine Carcinoma of the Breast is More Aggressive Than Breast Invasive Ductal Carcinoma: A Propensity Score Matching Study Based on SEER Database